Pharmaceuticalization of Society in Context: Theoretical, Empirical and Health Dimensions

Sociological interest in pharmaceuticals has intensified, heightening awareness of ‘pharmaceuticalization’. It is argued that pharmaceuticalization should be understood by reference to five main biosociological explanatory factors: biomedicalism, medicalization, pharmaceutical industry promotion and marketing, consumerism, and regulatory-state ideology or policy. The biomedicalism thesis, which claims that expansion of drug treatment reflects advances in biomedical science to meet health needs, is found to be a weak explanatory factor because a significant amount of growth in pharmaceuticalization is inconsistent with scientific evidence, and because drug innovations offering significant therapeutic advance have been declining across the sector, including areas of major health need. Some elements of consumerism have undermined pharmaceuticalization, even causing de-pharmaceuticalization in some therapeutic sub-fields. However, other aspects of consumerism, together with industry promotion, medicalization, and deregulatory state policies are found to be drivers of increased pharmaceuticalization in ways that are largely outside, or sub-optimal for, significant therapeutic advances in the interests of public health.

[1]  G. Salmon,et al.  Attention deficit hyperactivity disorder. , 2018, British journal of hospital medicine.

[2]  J. Abraham Partial progress: governing the pharmaceutical industry and the NHS, 1948-2008. , 2009, Journal of health politics, policy and law.

[3]  C. Davis,et al.  Drug Evaluation and the Permissive Principle , 2009, Social studies of science.

[4]  B. Marshall Sexual Medicine, Sexual Bodies and the ‘Pharmaceutical Imagination’ , 2009 .

[5]  K. Throsby The War on Obesity as a Moral Project: Weight Loss Drugs, Obesity Surgery and Negotiating Failure , 2009 .

[6]  P. Conrad,et al.  From Lydia Pinkham to Queen Levitra: direct-to-consumer advertising and medicalisation. , 2008, Sociology of health & illness.

[7]  F. Stevenson,et al.  Over-the-counter medicines: professional expertise and consumer discourses. , 2008, Sociology of health & illness.

[8]  Katie J. Ward,et al.  Pharma in the bedroom . . . and the kitchen. . . . The pharmaceuticalisation of daily life. , 2008, Sociology of health & illness.

[9]  Kathryn L. Jones In whose interest? Relationships between health consumer groups and the pharmaceutical industry in the UK. , 2008, Sociology of health & illness.

[10]  J. Abraham Sociology of pharmaceuticals development and regulation: a realist empirical research programme. , 2008, Sociology of health & illness.

[11]  Blair T. Johnson,et al.  Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration , 2008, PLoS medicine.

[12]  N. Britten Medicines and society , 2008 .

[13]  Órla O’Donovan Corporate Colonization of Health Activism? Irish Health Advocacy Organizations' Modes of Engagement with Pharmaceutical Corporations , 2007, International journal of health services : planning, administration, evaluation.

[14]  C. Davis,et al.  Deficits, Expectations and Paradigms in British and American Drug Safety Assessments , 2007 .

[15]  John Abraham,et al.  Interpellative Sociology of Pharmaceuticals: Problems and Challenges for Innovation and Regulation in the 21st Century , 2007, Technol. Anal. Strateg. Manag..

[16]  S. Majumdar,et al.  Drug treatments for obesity – Authors' reply , 2007, The Lancet.

[17]  P. Couzigou Drug treatments for obesity , 2007, The Lancet.

[18]  N. Bjarnason,et al.  Drug treatments for obesity , 2007, The Lancet.

[19]  Nikolas Rose Beyond medicalisation , 2007, The Lancet.

[20]  J. Bartlett,et al.  Anti-infective research and development--problems, challenges, and solutions. , 2007, The Lancet. Infectious diseases.

[21]  A. Trkola,et al.  Complement Lysis Activity in Autologous Plasma Is Associated with Lower Viral Loads during the Acute Phase of HIV-1 Infection , 2006, PLoS medicine.

[22]  E. Martin,et al.  The Pharmaceutical Person , 2006 .

[23]  J. Busfield Pills, Power, People: Sociological Understandings of the Pharmaceutical Industry , 2006 .

[24]  D. Healy The Latest Mania: Selling Bipolar Disorder , 2006, PLoS medicine.

[25]  Kalman D. Applbaum,et al.  Pharmaceutical Marketing and the Invention of the Medical Consumer , 2006, PLoS medicine.

[26]  Christine B Phillips Medicine Goes to School: Teachers as Sickness Brokers for ADHD , 2006, PLoS medicine.

[27]  A. Kleinman,et al.  The New Medical Oikumene , 2006 .

[28]  D. Pritchard Attention deficit hyperactivity disorder in children. , 2005, Clinical evidence.

[29]  A. Rafalovich Exploring clinician uncertainty in the diagnosis and treatment of attention deficit hyperactivity disorder. , 2005, Sociology of health & illness.

[30]  P. Conrad The shifting engines of medicalization. , 2005, Journal of health and social behavior.

[31]  Thomas R Fleming,et al.  Surrogate endpoints and FDA's accelerated approval process. , 2005, Health affairs.

[32]  H. Lofgren Pharmaceuticals and the consumer movement: the ambivalences of 'patient power'. , 2004, Australian health review : a publication of the Australian Hospital Association.

[33]  B. Chabner,et al.  Beyond fast track for drug approvals. , 2004, The New England journal of medicine.

[34]  C. May Medicines out of Control , 2004 .

[35]  J. Powers,et al.  Trends in antimicrobial drug development: implications for the future. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  Joe Collier,et al.  Let Them Eat Prozac , 2004, BMJ : British Medical Journal.

[37]  I. Crinson The Politics of Regulation within the ‘Modernized’ NHS: The Case of Beta Interferon and the ‘Cost-Effective’ Treatment of Multiple Sclerosis , 2004 .

[38]  Mauricio Castillo,et al.  Neurometabolic functioning and neuropsychological correlates in children with ADHD-H: preliminary findings. , 2004, The Journal of neuropsychiatry and clinical neurosciences.

[39]  D. Carpenter,et al.  The political economy of FDA drug review: processing, politics, and lessons for policy. , 2004, Health affairs.

[40]  Marcia Angell,et al.  The Truth About the Drug Companies , 2004 .

[41]  L. Stalley,et al.  The Influence of the Pharmaceutical Industry , 2004 .

[42]  Bruce Neal,et al.  Priority medicines for Europe and the world , 2004 .

[43]  Christian la Fougere,et al.  The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder , 2003, Neuroscience & Biobehavioral Reviews.

[44]  R. Kravitz,et al.  How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[45]  Andrew Herxheimer,et al.  Relationships between the pharmaceutical industry and patients' organisations , 2003, BMJ : British Medical Journal.

[46]  B. Djulbegovic,et al.  Pharmaceutical industry sponsorship and research outcome and quality: systematic review , 2003, BMJ : British Medical Journal.

[47]  A. Clarke,et al.  Biomedicalization: Technoscientific Transformations of Health, Illness, and U.S. Biomedicine , 2003, American Sociological Review.

[48]  J. Abraham Transnational industrial power, the medical profession and the regulatory state: adverse drug reactions and the crisis over the safety of Halcion in the Netherlands and the UK. , 2002, Social science & medicine.

[49]  Alan C. Evans,et al.  Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder. , 2002, JAMA.

[50]  J. Abraham,et al.  Progress, Innovation and Regulatory Science in Drug Development , 2002, Social studies of science.

[51]  Laurence Bervoets [Attention deficit hyperactivity disorder in children]. , 2002, Journal de pharmacie de Belgique.

[52]  J. Abraham,et al.  Citizenship, Medical Expertise and the Capitalist Regulatory State in Europe , 2002 .

[53]  H. Mantsch,et al.  Lessons from the glitazones , 2001, The Lancet.

[54]  J. Lexchin,et al.  Lifestyle drugs: issues for debate. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[55]  J. Collier Regulating Medicines in Europe: Competition, Expertise and Public Health , 2001, BMJ : British Medical Journal.

[56]  P. Le Courtois,et al.  Lessons from the glitazones. , 2001, Lancet.

[57]  R. Irwin,et al.  The diagnosis and treatment of cough. , 2000, The New England journal of medicine.

[58]  A. Daemmrich,et al.  RISK VERSUS RISK: Decision-making Dilemmas of Drug Regulation in the United States and Germany , 2000, Science as culture.

[59]  J. DiMasi,et al.  Measuring the Pace of New Drug Development in the User Fee ERA , 2000 .

[60]  J. Abraham,et al.  The therapeutic nightmare: the battle over the world's most controversial sleeping pill , 1999 .

[61]  A. R. Miller ‘Lifestyle’ drugs , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[62]  D. Bramble Attention deficit hyperactivity disorder in children , 1998, BMJ.

[63]  Myron Genel,et al.  Diagnosis and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents , 1998 .

[64]  J. Abraham,et al.  International Comparative Analysis and Explanation in Medical Sociology: Demystifying the Halcion Anomaly , 1998 .

[65]  R. Barkley Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. , 1997, Psychological bulletin.

[66]  R. Temple,et al.  Approval of new drugs in the United States. Comparison with the United Kingdom, Germany, and Japan. , 1996, JAMA.

[67]  H. Rothstein Science, Politics and the Pharmaceutical Industry , 1996 .

[68]  M. Schweitzer,et al.  Is there a U.S. Drug Lag? The Timing of New Pharmaceutical Approvals in the G-7 Countries and Switzerland , 1996, Medical care research and review : MCRR.

[69]  J. Abraham The production and reception of scientific papers in the academic-industrial complex: the clinical evaluation of a new medicine. , 1995, The British journal of sociology.

[70]  J. Abraham Distributing the Benefit of the Doubt: Scientists, Regulators, and Drug Safety , 1994 .

[71]  J. Abraham Bias in Science and Medical Knowledge: The Opren Controversy , 1994, Sociology.

[72]  L. Henderson On the Social System , 1993 .

[73]  Peter Conrad,et al.  Deviance and Medicalization , 1992 .

[74]  Peter Conrad,et al.  Medicalization and Social Control , 1992 .

[75]  P. M. Terry,et al.  Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. , 1991, The Journal of infectious diseases.

[76]  Rein Vos,et al.  Drugs Looking for Diseases , 1991, Developments in Cardiovascular Medicine.

[77]  Judith M. Rumsey,et al.  Cerebral glucose metabolism in adults with hyperactivity of childhood onset. , 1990 .

[78]  G. Canino,et al.  Impairment in the epidemiological measurement of childhood psychopathology in the community. , 1990, Journal of the American Academy of Child and Adolescent Psychiatry.

[79]  D. Rothman,et al.  New rules for new drugs: the challenge of AIDS to the regulatory process. , 1990, The Milbank quarterly.

[80]  M. Dessens-Kroon,et al.  INCREASED TETRACYCLINE RESISTANCE IN GONOCOCCI IN THE NETHERLANDS , 1989, The Lancet.

[81]  Michael Bury,et al.  Tranquillisers as a Social Problem , 1988 .

[82]  John E. Chubb The Political Economy of Federalism , 1985, American Political Science Review.

[83]  W. Fitzgerald Corporate Crime in the Pharmaceutical industry , 1984 .

[84]  I. K. Zola,et al.  Medicine as an Institution of Social Control , 1972, The Sociological review.

[85]  E. Freidson The Profession of Medicine , 1923 .